Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1800 articles with Sanofi (France)
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
For diabetic patients, achieving a certain “time in range” is a more realistic glucose control strategy than striving for a particular daily target, according to researchers working with Sanofi who spoke during the 56th Annual Meeting of the European Association for the Study of Diabetes.
-
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
-
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
-
Results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
-
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
-
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
-
Another Kevzara study in hospitalized COVID-19 patients failed to meet primary and secondary endpoints.
-
In a regulatory filing with the U.S. Securities and Exchange Commission, Translate Bio indicated that the COVID-19 vaccine it is developing with Sanofi induced an immune response in non-human studies.
-
Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.
-
Three months after joining forces to develop an adjuvanted vaccine for COVID-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
-
Sanofi is lining up to spin off its active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.
-
Rumors are flying that Paris-based Sanofi has a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies. At the top of the list, reportedly, is South San Francisco-based Principia Biopharma.
-
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
-
They will focus on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such and rheumatoid arthritis.
-
Kiadis Pharma, based in Amsterdam, The Netherlands, licensed a previously undisclosed K-NK0004 program to Paris-based Sanofi.
-
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
-
Sanofi Pasteur and Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases. The original deal was entered in 2018.
-
Sanofi announced plans to increase its vaccines research and production capabilities. As part of the plan it will invest $679.4 million (€610 million) to create a new production site and a research center, both in France.
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.